Table 3.
Epidemiological characteristics of prostate cancer patients with confirmed SARS-CoV-2 infection in Veneto, treated with or without androgen-deprivation therapy
| PCa in ADT | PCa non-ADT | OR (95% CI) | Other tumors | OR (95% CI) | |
|---|---|---|---|---|---|
| Cancer patients in Veneto Region population | 5273 | 37 161a | 84934a | ||
| Total no. of SARS-CoV-2-positive | 4 | 114 | 4.05 (1.55–10.59) P = 0.0043 |
312 | 4.86 (1.88–12.56) P = 0.0011 |
| Mild disease | 3 | 83 | 3.93 (1.31–11.77) P = 0.0144 |
223 | 4.62 (1.56–13.69) P = 0.0057 |
| Non-hospitalized | 1 | 7 | 9 | ||
| Hospitalized | 2 | 76 | 214 | ||
| Severe disease | 1 | 31 | 4.40 (0.76–25.50) P = 0.0982 | 89 | 5.53 (0.97–31.58) P = 0.0544 |
| Intensive care (ICU) | 1 | 13 | 32 | ||
| Deceased | 0 | 18 | 57 | ||
| Estimated total SARS-CoV-2-positive cases/100 000 | 76 | 307 | 367 |
PCa patients with ADT were considered as reference for OR calculation. Patients are presented referring to the degree of infection severity.
ADT, androgen-deprivation therapy; CI, confidence interval; OR, odds ratio; PCa, prostate cancer; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
Prevalent cancer patients’ data are as of January 1st, 2016 (source: Veneto Tumor Registry. Available at https://gecoopendata.registrotumoriveneto.it/prevalenza.php?lang=EN).